导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.02% | 1291/4773 |
| 近一周 | -2.06% | 1145/5462 |
| 近一月 | 1.17% | 416/5421 |
| 近一季 | 1.08% | 582/5209 |
| 近半年 | -4.08% | 2414/4920 |
| 近一年 | 4.61% | 1692/4366 |
| 近两年 | 28.07% | 2358/2954 |
| 近三年 | 21.14% | 1429/2253 |
| 成立以来 | 92.36% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.35% 534/4961 |
-10.71% 4161/5312 |
- - |
- - |
| 2025 | 3.66% 3107/4813 |
-2.72% 2965/3635 |
2.60% 1470/4076 |
2.54% 3789/4524 |
1.28% 1436/4813 |
| 2024 | 17.92% 636/3463 |
8.28% 193/2808 |
2.33% 356/3014 |
8.80% 2723/3129 |
-2.18% 1996/3463 |
| 2023 | 5.72% 182/2656 |
5.14% 822/2280 |
0.84% 270/2385 |
4.34% 153/2515 |
-4.43% 1031/2655 |
| 2022 | -1.03% 44/2207 |
1.85% 90/1919 |
-0.79% 1654/2016 |
-2.26% 34/2113 |
0.21% 1525/2208 |
| 2021 | 20.05% 186/1822 |
5.44% 110/1255 |
9.76% 523/1330 |
4.89% 312/1466 |
-1.11% 1312/1822 |
| 2020 | 13.30% 804/1250 |
-9.17% 660/1028 |
6.49% 862/1067 |
12.22% 400/1164 |
4.39% 844/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 易方达中证红利ETF VS. 长安沪深300非周期A(740101) |